Email Us

Genetic Testing for BRCA1/2 Targeted-Drug Guidance (Germline + Somatic) CapitalBio

This test detects somatic and germline SNVs, InDels and CNVs mutations in the BRCA1 and BRCA2 genes, covering the entire coding regions of the BRCA1/2 gene and both flanking intron regions, providing information to guide PARP inhibitor therapy in breast and ovarian cancer.

targeted medication guidance for brca1 2

Applicable Population of Targeted Medication Guidance for BRCA1/2

  • Cancer patients in need of PARP inhibitors.

  • Cancer patients requiring BRCA1/2 genetic testing.

Specification of Targeted Medication Guidance for BRCA1/2

Sample typesFresh tissue + venous blood / Paraffin specimen + venous blood / Venous blood
TAT10 working days


Products
Contact with CapitalBiotech
Contact Information
Your Inquiries (Expandable)
Instruments
Detection Kits/Reagents
Research Services
Biochip Design & Fabrication
Diagnostic Services
86-10-69002900
Building C, Block 88 Kechuang 6th Street, Yizhuang Biomedical Park, Beijing